Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens
September 06, 2014 12:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and
Hartford Hospital today announced in vitro results from an
investigator-sponsored study that highlight delafloxacin's...
Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting
September 04, 2014 10:45 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that an additional three abstracts have been accepted as
late-breakers at the annual Interscience Conference...
Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy
August 14, 2014 10:38 ET
|
Scienta Communications
NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Christopher Kiritsy to the Company's
Board of Directors. Mr. Kiritsy is currently president,...
Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
July 24, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that the company and investigators will be making eight
presentations at the annual Interscience Conference...
Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test
March 26, 2014 07:30 ET
|
Zyomyx
FREMONT, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc. has been awarded US$7.5 million from UNITAID to commercialize its quantitative MyT4™ point-of-care CD4 test, designed to guide...
Increase Your Food Safety Knowledge
March 03, 2014 16:17 ET
|
Center for Food Integrity
MISSION, KS--(Marketwired - Mar 3, 2014) - (Family Features) From understanding the role of antibiotics in animal and food production to implementing a safety strategy within your own home, a...
Fedora Pharmaceuticals Demonstrates that FPI-1465 Increases Activity of Certain Antibiotics against Drug-Resistant Bacteria
September 12, 2013 13:00 ET
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. and its collaborators presented
results of preclinical studies demonstrating that FPI-1465 increases
the activity of...
Fedora Pharmaceuticals Unveils Details of Antibiotic Resistance Program in 10 Posters at 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
August 27, 2013 08:00 ET
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta, Aug. 27, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced that the Company
and its collaborators will be presenting 10 posters at the upcoming
Interscience...
Fedora Pharmaceuticals Appoints Ronald Odynski and Dr. Leonard Post to Newly Created Board of Directors
October 31, 2012 08:00 ET
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta, Oct. 31, 2012 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced the creation of a
Board of
Directors and appointment of Leonard E. Post, Ph.D. and Ronald
W. Odynski,...
Fedora Pharmaceuticals Appoints Thomas R. Parr, Ph.D., Chief Scientific Officer
September 05, 2012 10:00 ET
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced the appointment of
Thomas Parr,
Ph.D. to the newly created role of chief scientific officer.
Dr. Parr...